Many neuropsychiatric risk genes contribute to epigenetic regulation of gene expression but very little is known about specific chromatin-associated mechanisms governing the formation and maintenance of neuronal connectivity. Here we show that transcallosal connectivity is critically dependent on C11orf46 (also known as ARL14EP), a small nuclear protein encoded in the chromosome 11p13 Wilms Tumor, Aniridia, Genitourinary Abnormalities, intellectual disability (formerly referred to as Mental Retardation) (WAGR) risk locus.
Introduction
A wide range of neurodevelopmental disorders manifesting in infancy and early childhood (including intellectual disability and autism spectrum disorder) or young adulthood (including schizophrenia) are associated with disrupted interhemispheric communication, which in some but not all of the affected cases is accompanied by structural alterations of the corpus callosum, the brain's largest commissure [1] [2] [3] . The formation of interhemispheric connectivity involves a highly orchestrated multi-step process, including midline zipper glia promoting hemispheric fusion and midline crossing of pioneer fibers, followed by ingrowth of large numbers of transcallosal axons interconnecting the left and right cerebral cortex 4 . Early occurring disruptions of callosum (CC) and posterior CC volumes but not for other individual portions of the corpus callosum. After adjusting for age and sex, patients with isolated PAX6+/-(N=12) had significantly smaller total (p<0.001) and posterior (p=0.001) CC volumes than controls (N=23), a finding consistent with the role of PAX6 in morphologic brain development 15, 16 . However, patients with combined PAX6/C11orf46+/-(N=27) had an even smaller posterior CC volume compared to both patients with isolated PAX6+/-(p=0.003) and controls (p<0.001) (Fig. 1a,b) . Because of the established role of BDNF in brain development and intellectual functioning 17 , we also considered a potential confounding effect of BDNF+/-. We observed no significant differences in the PAX6/C11orf46+/-patients with (N=17) and without (N=10) BDNF+/-for total or posterior CC volumes (p=0.19 and 0.47, respectively, for unadjusted comparisons; p=0.13 and 0.37, respectively, on ANCOVA adjusting for age and sex) ( Supplementary Fig. 1a ). Lymphoblastoid cell lines from C11orf46 haploinsufficient WAGR cases have approximately 50% lower C11orf46 protein and mRNA levels, indicating that the expression of the remaining intact allele does not undergo compensatory upregulation ( Supplementary   Fig. 1b) . Therefore, loss of one C11orf46 copy in the context of chr. 11p13-14.1 microdeletions appears to be more highly detrimental for neurodevelopment and associated with more severe hypoplasia of the callosal commissure.
Having linked C11orf46 haploinsufficiency to callosal hypoplasia, we next explored C11orf46 expression patterns in mouse brain. In the cerebral cortex, C11orf46 quantification at the level of mRNA, and protein with a custom-made anti-C11orf46 antibody ( Supplementary Fig. 1c ) showed its expression across a wide age window, with higher levels in the pre-and post-natal developmental periods as compared to the adult brain ( Fig.   1c-f ). C11orf46 was mainly expressed in the cortical plate (CP) with minimal labeling in the proliferative subventricular zone (SVZ) (Fig. 1e) , with punctate and intranuclear distribution predominantly in neuronal nuclei as confirmed by co-staining with NeuN antibody (Fig. 1f) . Additional double-labeling experiments confirmed that C11orf46 is predominantly expressed in Calmodulin-kinase II (CaMKII)-positive glutamatergic neurons but not in glial fibrillary acid protein (GFAP)-positive astrocytes or Olig2-positive oligodendrocytes and precursors, or Iba1-positive microglia (Fig. 1g) . C11orf46 immunoreactivity in GABAergic neurons was much weaker than those in glutamatergic neurons (data no shown). We conclude that in the developing cerebral cortex, C11orf46 is primarily expressed in post-migratory glutamatergic cortical neurons.
To explore the role of C11orf46 in developing cortex, we knocked down its expression by in utero electroporation (IUE). We delivered C11orf46 (shRNA1, shRNA2) or control short hairpin RNAs (shRNAs) together with green fluorescent protein (GFP) expression plasmid using our published protocols [18] [19] [20] [21] . We selected embryonic day 15 (E15) for IUE procedure with two reasons: first, C11orf46 is highly expressed at E15 (Fig. 1c,d) . Second, at this stage IUE mostly targets progenitor cells in the ventricular zone (VZ) which later differentiate into cortical layer II/III pyramidal neurons 22, 23 , approximately 80% of which become transcallosal projection neurons 24 as our cell type-of-interest given the clinical phenotype reported above.
Indeed, E15 IUE C11orf46 knockdown resulted in severe arborization deficits in GFP-labeled callosal axons projecting into the contralateral cortex at postnatal day 14 (P14) (Fig. 1h,i) . This phenotype was highly dependent on the level of C11orf46 knockdown. More severe axonal arborization deficits by C11orf46 shRNA1
( Fig. 1i ) was associated with stronger knockdown effect on C11orf46 compared with shRNA2
( Supplementary Fig. 1d ). Importantly, these axonal arborization deficits were partially rescued by coexpressing shRNA resistant wildtype C11orf46. Strikingly however, an shRNA resistant C11orf46 (R236H) mutant protein carrying a disease-associated non-synonymous point mutation that consists of arginine to anti-C11orf46 antibody in HeLa cells, and in homogenates of human cerebral cortex confirmed that C11orf46 assembles with SETDB1, MCAF1 and other regulators of repressive chromatin, including heterochromatinassociated protein 1 gamma (HP1γ) ( Fig. 2n and Supplementary Fig. 2f ). These results suggest that C11orf46 may function as a chromatin regulator in the SETDB1 complex (Fig. 2o) . Table 4) . Notably, among these 41 genes, we found that 17 genes are reportedly involved in axonal development. However, given that the observed gene alterations were likely confounded by deletion of other proximal genes with C11orf46 at WAGR locus, we switched in our next set of experiments to neuron-like NSC34 Tet-On cells expressing C11orf46 shRNA to further examine C11orf46-regulated genes. We found that expression levels of 17 axonal growth and development genes were altered in response to C11orf46 shRNA (Fig. 3a) . Next, we wanted to confirm C11orf46's role as a transcriptional regulator during brain development, focusing on the top three candidate genes from our aforementioned NSC-34 studies, as defined by significant expression changes in response to C11orf46 knockdown and with KAP binding sites proximal to transcription start site (TSS) (+/-750b) 33 . These include Doublecortin-like kinase 1 (Dclk1) which is essential for axon tract formation across the anterior commissure in the ventral forebrain and the corpus callosum 34 , Sema6a which encodes a PLXNA4 protein ligand 35, 36 , and Gap43 which encodes a growth cone protein essential for commissural axon guidance 37 (Supplementary Table 4) . To confirm C11orf46's role as a transcriptional regulator during brain development, we knocked down C11orf46 by IUE-mediated delivery of C11orf46shRNA together with GFP expression plasmid at E15 and GFP-labeled projection neurons were isolated by Fluorescence-Activated Cell Sorting (FACS) at P0 (Fig. 3b) . Notably, Sema6a was significantly increased in C11orf46 knock-down projection neurons (Fig. 3c) However, because '1:1' systems (one transcriptional regulator per dCas9 copy) are often only minimally effective 38,39 , we instead used dCas9-SunTag protein scaffolds which assembles as a binary system with the protein of interest fused to a single-chain antibody variable fragment (scFv)-green fluorescent protein cassette, with the scFv binding to the Cas9-fused protein scaffold carrying 10 or more copies of GCN4 (the scFv epitope) 39 . We built a dCas9-SunTag system to load ten copies of C11orf46, or the VP64 activator protein as a positive control, onto a single sgRNA-target sequence (Fig. 4a) . We began with our epigenome editing experiments in HEK293 cells selecting SEMA6A, DCLK1, and GAP43. For each gene, we obtained four sgRNAs positioned within 500bp upstream of the target TSS. For each of the 3 target genes, three groups of HEK293 cells were compared, based on transfection with (1) dCas9-ST alone (sgRNA-dCas9-10xGCN4 'SunTag' ) or dCas9-ST together with one of the following plasmids, (2) scFv which recognizes the GCN4 epitope on dCas9-STsuperfold GFP-VP64, or (3) scFv-superfold GFP-wild type C11orf46 (C11orf46 wt ) (Fig. 4a) . After nuclear localization of the scFv-sfGFP-C11orf46 domain was confirmed (Fig. 4b) , testing for each target gene experiments were conducted in parallel in HEK293 cells, with each of the four sgRNA tested individually and in a pool of four. Interestingly, introduction of 3 of the 4 sgRNAs to SEMA6A which is expressed at much higher levels as compared to the other test genes (Fig. 4c) , resulting in significant decrease in SEMA6A expression when co-transfected with the dCas9-ST 10x C11orf46 (wt) systems (Fig. 4d) . Conversely, DCLK1 and GAP43, which is expressed at extremely low levels at baseline (Fig. 4d) , showed minimal changes when cotransfected with dCas9-ST 10x C11orf46 (wt) , while responding to dCas9-ST 10xVP64 with a robust, at least 5-10 fold increase in their expression (Fig. 4d) .
Suppression of
Our studies in HEK293 cells suggest that C11orf46, when tethered in multiple copies to specific promoter sequences via the CRISPR-Cas9-SunTag system, could actively repress transcribed genes. Next, we wanted to explore this approach in vivo in developing upper layer cortical projection neurons of somatosensory cortex. We focused on Sema6a, which both were de-repressed after C11orf46 knockdown in NSC34 cells and GFP-positive neurons (Fig. 3a,c) . Two sgRNAs, targeting different sequences within the first 500bp upstream from the TSS of Sema6a, were selected for in vivo studies and delivered at E15 (Fig. 4e) . Strikingly these Sem6a promoter-targeting sgRNAs fully rescued the transcallosal axonal arborization deficit normally encountered upon C11orf46 knockdown at E15 by IUE (Fig. 4f,g ). Consistent with C11orf46's association with KMT-RC, introduction of Sema6a sgRNA also resulted in increased H3K9me3 levels at the Sema6a promoter, in striking contrast with a decrease in H3K9me3 levels after C11orf46 knockdown (Fig. 4h) . These effects were highly specific for the target gene sequence, because sgRNAs directed against Dclk1 promoter did not affect the Sema6a promoter (Fig. 4h) . Likewise, increased Sema6a expression in C11orf46 knockdown neurons was strongly suppressed by our SunTag-based C11orf46-mediated epigenome editing toolkit targeting the Sema6a, but not the Dclk1 promoter (Fig. 4i) 
Discussion
Axonal development is a pivotal developmental process in establishing neural connectivity for brain functions, In this study, we showed that C11orf46 assembles with bona fide factors of histone-3 lysine-9 trimethyltransferase (H3K9me3) SETDB1 complex, it substrate histone H3 and a subset of nuclear proteins functionally associated with repressive and heavily H3K9-methylated (hetero) chromatin, including LMNB1, LAP2A and HP1γ. These multi-molecular assemblies of chromatin-bound proteins presumably require distinct domains of C11orf46 to associate with SETDB1 complex and histone H3. Importantly, non-synonymous genetic mutations G218E and R236H found in the CRD domain of C11orf46 are associated with neurodevelopmental disease conditions 13, 49 . We show that specifically the R236H, disrupted the C11orf46 assembly with the SETDB1 complex but not C11orf46's association with histone H3. Therefore, mutations in critical domains of C11orf46 could disrupt the above assembly and potentially interfere with spatiotemporal gene silencing required for orderly development of transcallosal connectivity. Notably, purified C11orf46
showed strong affinity for histone H3 tail modifications in vitro; we were surprised to observe C11orf46's high affinity towards a histone mark antagonizing histone methylation, H3R2-citrulline (H3R2Cit) 50, 51 . Future studies will explore in more detail the regulatory role for C11orf46. For example, C11orf46 could sense the levels of mono-or di-methylated H3K9 to promote trimethylation, or block H3K9 methylation in response to high levels of antagonizing H3R2Cit mark.
In addition to protein components of the SETDB1 complex, such as KAP1 and MCAF1, our results of proteome screening identified LMNB1 and LAP2A, two nuclear lamina proteins that were previously discovered at the heterochromatin rich nuclear periphery 52 , as potential protein interactors of C11orf46.
Interestingly, LMNB1 and LAP2A play critical roles for developmentally regulated dendritic and axonal connectivity 53 . Because C11orf46 resulted in impaired axonal development, but had no robust effect on dendritic structure, it will be important to further investigate epigenetic mechanisms to determine how C11orf46 specifically regulates axonal development.
To the best of our knowledge, this is the first study demonstrating the utility of the nuclease-deficient CRISPR/Cas9 system-mediated epigenome editing with IUE knockdown approach for addressing cellautonomous epigenetic machinery for regulation of transcallosal connectivity. By targeting transcallosal
projection neurons, we demonstrate that C11orf46 regulates axonal terminal arborization by control of expression of Sema6a via epigenomic promoter H3K9-methylation. The corpus callosum phenotypes in WAGR cases with C11orf46 haploinsufficiency ( Fig. 1 ) and the successful epigenomic rescue by sequence-specific C11orf46-mediated chromatin remodeling (Fig. 4) , would imply that future chromatin-based therapies could be harnessed to correct developmental errors in the brain's connectome. However, because the WAGR CNV encompasses a large genomic regions that encompass many genes, hampering identification of genetic drivers responsible for specific phenotypes shown in CNVs-associated disease conditions, our data do not exclude the possibility that other genes in 11p13 deletion region, besides BDNF, PAX6, and C11ORF46 may have independent effect on axonal and other anatomical phenotypes as well as behavioral outcomes in WAGR syndrome. Furthermore, since all patients with C11orf46+/-also had PAX6+/-in our cohort, the phenotype of isolated C11orf46+/-is unknown (although homozygous mutations in C11orf46 have been reported in association with intellectual disability) and there remains the possibility that additional loss of PAX6+/-may be required for C11orf46+/-to cause significant defects in morphologic brain development.
In summary, we identified a chromatin-associated mechanism underlying axonal development and show that
C11orf46 plays an important role in transcallosal phenotypes in 11p13 deletion syndrome. Further investigation on epigenetic regulators in CNVs associated with neurodevelopmental disorders and altered neural connectivity is important for translational approaches that pave the way for novel treatment of neurodevelopmental psychiatric conditions in early life.
Methods
Human subjects. Patients who had prior genetic testing confirming diagnosis of WAGR/11p13 deletion syndrome or isolated aniridia with known PAX6 mutation or deletion, as well healthy control subjects who had no chronic medical conditions were recruited through local advertisements and on-line postings. Genetic testing. Deletion boundaries for each subject with WAGR syndrome were determined using oligonucleotide array comparative genomic hybridization using a custom-designed microarray platform (Agilent Technologies, Inc., Santa Clara, CA) containing 105,000 60-mer oligonucleotide probes using NCBI Build 36 (hg18) human reference sequence as previously described 54 . Probes for chromosome 11p were spaced at approximately 400 bp intervals (excluding repeat regions) using 57,925 probes; 121 probes were located within BDNF.
Brain magnetic resonance imaging (MRI).
Brain MRI consisted of one cubic millimeter resolution, T1-weighted images collected on a 3.0 T Philips Achieva MRI scanner with an 8-channel phased array head coil.
Corpus callosum volumes were calculated using FreeSurfer's (version 5.3) subcortical image processing pipeline and published methods 55 . Briefly, the pipeline uses prior probability of a given tissue class at a specific atlas location, the likelihood of the image intensity given the tissue class, and the probability of the local spatial configuration of labels given the tissue class. The measured corpus callosum volume extends 2.5 mm from the midline on both sides to mitigate against any residual misalignment after registration to the template. Table   3 ). Peripheral blood mononuclear cells were isolated using a Ficoll-Paque gradient (GE Heathcare Life Sciences, Pittsburgh, PA), then infected with Epstein Barr virus, and after sufficient cell line expansion, stored in freezing media at -80°C.
Lymphoblastoid cell lines. Fasting venous blood samples were obtained from patients (Supplementary

Antibodies.
A mouse monoclonal antibody against Flag-tag (M2) (Sigma, Cat #F1804) was used for affinity purifications. For immunoblots, the following antibodies were used: rabbit monoclonal antibody against the Cterminus of human SETDB1 (Cell Signaling technology, Cat #2196S), KAP1 (cell signaling technology, Cat#4124S); rabbit polyclonal antibody against SETDB1 (Santa Cruz, Cat #sc-66884X), MCAF1 (Novus biological, Cat #NB100-438), Histone H3 C-terminus (Millipore, Cat #07-690). Custom-made mouse monoclonal antibody and guinea pig polyclonal antibody were generated against E. coli derived, purified and mass spectrometrically verified full-length human His-tagged C11orf46 protein (Supplementary Fig. 2b ). For details on the generation of mouse monoclonal antibody, see the references 56,57 . Altogether, total 45
individually picked anti-C11orf46 mouse monoclonal hybridoma clones were screened by Western blot using E.coli derived human C11orf46 as antigen. Five clones (clone numbers 9, 26, 28, 33, and 36) were positive in this assay (clone 26 shown as representative example in Supplementary Fig. 2b ). Antibodies from these clones were pooled and used for the co-immunoprecipitation assay using tissue homogenates of human prefrontal cortex. The guinea pig antibodies were generated by Cocalico Biologicals (Reamstown, PA) using affinity purified human recombinant His-tagged full-length C11orf46. Rabbit polyclonal antibodies against histone H3 lysine-9 monomethyl (Millipore, Cat #07-450), H3 lysine-9 dimethyl (Upstate, Cat #07-441), and H3 lysine-9 trimethyl (Upstate, Cat #07-442) were used for co-immunoprecipitating endogenous SETDB1 from HeLa nuclear extract.
Plasmids. Plasmids expressing interfering short hairpin RNA (shRNA) were generated to suppress endogenous C11orf46 protein expression utilizing the pSUPERIOR.puro vector system (Oligoengine). Their target sequences are: C11orf46 shRNA-1 with strong suppression; 5'-CAAACTGAATTTGCTCCAGAA-3' and C11orf46 shRNA-2 with milder suppression; 5'-GAAGACAGCTTGTACCTGGTT-3'. A scrambled sequence that shows no homology to any known messenger RNA was utilized to produce the Control shRNA (5'-ATCTCGCTTGGGCGAGAGTAAG-3'). The HA and scFv-tagged RNAi resistant wild-type human C11orf46 expression constructs containing four silent mutations (underlined) in the target sequence of C11orf46 shRNA (5'-CAAACAGAGTTCGCACCAGAA-3') were produced and cloned into CAG promoter driven plasmid (pCAGGS1vector) for rescue experiments. dCas9-SunTag coding sequence was also transferred into pCAGGS1
vector. Two single guide RNA sequences each Dclk1 or Sema6a promoter region were using online CRISPR design tool 58 . Those protospacer sequences were cloned into sgRNA cloning vector (Addgene #41824) with the protocol distributed on the addgene website (https//media.addgene.org/data/93/40/adf4a4fe-5e77-11e2-9c30-003048dd6500.pdf). The protospacer sequences are listed in Supplementary Table 5 .
In vitro epigenomic editing system using dCas9-SunTag-C11orf46. For producing scFv-GCN4-sfGFPC11orf46, full-length wild type C11orf46 (C11orf46 wt ) or R236H mutant C11orf46 (C11orf46 R236H ) was cloned in-frame to the C-terminus of scFv GCN4 antibody using the BamH1 and NotI sites (addgene plasmid #60904).
dCas9-SunTag (2µg, addgene #60903) containing 10 copies GCN4 peptide epitope fused to catalytically inactive Cas9 was delivered into HEK293FT cells (1.5X10 6 , 60mm dish) along with a 4 pooled sgRNAs (50ng each sgRNA, U6-sgRNA-polyT amplicon) to direct GCN4 single-chain antibody conjugated fluorescent C11orf46 (2µg, scFv-GCN4-sfGFP-C11orf46) to neurite-regulating gene promoters. Three days after transfection using lipofectamine 2000, total RNA was extracted and qPCR was performed. scFV-GCN4-sfGFP-VP64 was used as a positive control for activating gene expression. dCas9 alone was tested as a negative control to account background gene activity. For producing U6-sgRNA-polyT, mouse [Dec.2011 (GRCm38/mm10)] and human promoter sequences (500 bp) were identified using PromoterWise (http://www.ebi.ac.uk/Tools/psa/promoterwise/). Four sgRNAs spaced approximately 500bp away from each other in the promoter region of the target genes were identified based on their high gRNA score and low/no off-target site in the genome (Supplementary Table 5 ). sgRNAs were incorporated into U6-sgRNA-polyT cassettes by PCR amplification using U6-Fwd and U6sgRNAter-Rev primers which carried the reverse complement of part of the U6 promoter. These cassettes include the sgRNA (+85) scaffold with guide sequence and seven T nucleotides for transcriptional termination.
In utero electroporation (IUE). IUE targeting the somatosensory cortex was performed using our previously published methods with minor modifications 20, 21 . Pregnant C57/BL6 mice were anesthetized at embryonic day RNA-seq and bioinformatic analysis. Total RNA was isolated from four lymphoblastoid cell lines including one derived from healthy control subject, one WAGR patient with C11orf46 gene intact and two WAGR patients with C11orf46 gene deletions using a total RNA extraction kit (Qiagen) according to manufacturer instructions. RNA integrity determined in Bioanalyzer (Agilent's Technologies) and a total RNA-seq was performed at Eurofins genomics. DNA libraries were prepared from total RNA samples, the adaptor-ligated libraries (125bp) were enriched by PCR amplification and gel purified (average library size of ~270bp).
Libraries were sequenced with the Genome Analyzer II (Illumina) using pair-end 50-bp raw fastq reads. The sequencing approach resulted in 32,750,145 and 27,929,697 and 39,292,408, and 54,377,092 reads for lymphoblastoid cell line sample numbers one, two, three, and four, respectively. Sequencing raw reads were assessed for quality control using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). RNAseq reads of 50 bp were aligned against the human genome (UCSC hg19) references with TopHat2 using default parameters with Bowtie as the internal aligner and a segment mapping algorithm to discover splice junctions 59,60 . 77 to 82% percent of all unique sequences correctly aligned to the reference genome. Reads were counted in exon regions using featureCounts tool (subread v1.5.2) producing a table that was normalized to rpkms (Supplementary Table 3 Both methods yielded highly reproducible results in the expression measurements of the transcripts, and the majority of differentially expressed genes were also significant in an independent analysis using Cufflinks. Pelleted cells were suspended in CS100-0.02 buffer (Tris HCl, pH 7.4, 10 mM MgCl2, 2.5 mM NaCl, 100 mM 0.02% NP-40, 2 units/ml Benzonase, protease inhibitor, and phosphatase inhibitor) at four times, packed cell volume, sonicated, passed five times through a 26-gauge needle, centrifuged at 20,000 x g for 15 min, and filtered through a 0.2-μm filter (Millipore, Cat #SCGP00525). Benzonase was added to eliminate nucleic aciddependent indirect interactions. Lysate was passed through an anti-FLAG agarose column (packed using 0.5 ml of 50% slurry per 100 mg of extracts) at 4 °C and washed four times with cold CS100-0.02, then four times with cold CS500-0.02 (Tris HCl, pH 7.4, 10 mM MgCl2, 2.5 mM NaCl, 500 mM 0.02% NP-40, protease and phosphatase inhibitors). Column-bound protein complexes were eluted using 10 bed volumes of the CS100-0.02-containing 3X-FLAG peptide (100ng/µl) at 4 °C. Purity of protein complexes was verified with four to fifteen percent gradient gel/silver stain and analyzed using mass spectrometry at the proteomics core facility in University of Massachusetts.
Immunohistochemistry. Immunohistochemistry was performed using our previously published methods with some modifications 20,21 . Mouse brains were extracted after perfusion with 4% paraformaldehyde (PFA). The fixed brains were embedded in cryocompound (Sakura) after replacement of PFA with 30% sucrose in phosphate buffered saline (PBS). Coronal sections including somatosensory cortex were obtained at 40 µm with a cryostat (Leica, Cat #CM 3050S). The sections were washed with PBS containing 0.5% Triton X-100 and then blocked with 0.5% Triton X-100 and 1% bovine skin gelatin for one hour. After blocking, sections were incubated with mouse monoclonal anti-NeuN (Millipore, Cat #MAB377) and guinea-pig polyclonal antiC11orf46 primary antibodies at 4°C overnight, followed by incubation with secondary antibodies conjugated to Alexa 488 and 568 (Invitrogen, Cat #A11001 and A11075 respectively) for one hour. Nuclei were labeled with DAPI (Roche, 10236276001). For cell type marker staining, anti-CaMKII (Millipore, Cat #05-532), anti-Olig-2 (Millipore, Cat #AB9610), anti-GFAP (Sigma, Cat #G3893), or anti-Iba-1 (Wako, Cat #019-19741) antibody were used. For analysis of neuronal migration and axonal outgrowth, coronal sections from fixed brains were obtained at 20 µm and 100 µm, respectively. The sections were washed with PBS containing 0.5% Triton X-100 and then blocked with 0.5% Triton X-100 and 5% normal goat serum for one hour. After blocking, sections were incubated with rat monoclonal anti-GFP (Nacalai, Cat #GF90R) antibody at 4°C overnight, followed by incubation with secondary antibodies conjugated to Alexa 488 for one hour.
Fluorescence-Activated Cell Sorting (FACS).
The mice subjected to IUE at E15 underwent whole brain extraction at P0 or P14. The somatosensory cortex where GFP-positive neurons were localized was dissected using a stereomicroscope with a fluorescent flashlight (Night Sea, Cat #DFP-1). Cells were separated by utilizing papain dissociation kit (Worthington, Cat #LK003150) with minor modification 62 . For ChIP-qPCR experiments, approximate 0.5-1.0 x 10 6 GFP-positive neurons obtained by pooling 5-6 pups' GFP-positive cortices were collected by FACS into 1.5ml Protein LoBind Tube (Eppendorf, Cat #Z666505).
Quantitative real time PCR (qPCR). FAC-sorted GFP positive somatosensory cortical neurons were
suspended into RNAlater solution (ambion Cat#AM7021) and stored at -80°C. Total RNA were prepared and treated by DNAse (PicoPure™ RNA Isolation Kit, Applied Biosystems Cat#KIT0204). Total RNA was reverse transcribed to cDNA (SuperScript™ III First-Strand Synthesis System, Invitrogen Cat#18080051). qPCR was performed using PowerUp™ SYBR™ Green Master Mix (Applied Biosystems Cat#A25742). Hprt1 was used as a reference gene to normalize the expression data by ddCt method. Target gene primers (Sema6a, Dclk1, Gap43, and Hprt1) are listed in Supplementary Table 6 section. Acquisition parameters were kept constant for all scans. The signal intensity of GFP in the somatosensory cortex was divided by its intensity in the white matter. Five mice were used for quantification for each group. All calculations were performed using ImageJ software.
Statistical analyses:
For analysis of MRI data, ANOVAs accounting for age and sex as covariates compared white matter structure volumes among patient groups. One-way ANOVA with the Bonferroni multiple comparison test was used for factorial analysis among more than three groups. Student's t-test was used for comparisons between two groups. All data are shown as mean ± SEM, unless otherwise mentioned. when compared with control shRNA (first 3 panels); this axonal deficit was partially rescued by co-expressing RNAi resistant wild type C11orf46 (C11orf46 Wt ), but not by R236H mutant (C11orf46 R236H ), panels 4 and 5 from left. n = 5-14 mice per condition. F (4, 43)=, P < 0.0001. **P < 0.01, ***P < 0.001, ****P < 0.0001 determined by one-way ANOVA with post hoc Bonferroni test. Scale bar, 100µm. j, k C11orf46 knockdown did not have an effect on radial neuronal migration at P2 (j) or dendritic structures of GFP-labeled pyramidal neurons in the somatosensory cortex at P14 (k). Scale bar, 50μm. knockdown (p=0.0085). *P < 0.05, **P < 0.01, ***P < 0.001 determined by Student's t-test test. n = 10-19 independent mice per condition. All data were normalized by the HPRT1 transcript. **** *** ** **** h i Fig. 4 
